The Ideal Way to Use Quizartinib to Treat AML
Mark J. Levis, MD, PhD, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).
Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the ideal way to use quizartinib to treat a patient with an FLT3-ITD mutation in acute myeloid leukemia (AML).
Clinical Pearls:
- The ideal way to use a FLT3 inhibitor is to introduce it upfront with induction therapy in a newly diagnosed patient with FLT3-ITD AML
- Studies using “not as effective” FLT3 inhibitors still show a considerable amount of efficacy with this procedure
- Patients should be treated into remission until the patient can receive an allogeneic transplant and then a FLT3 inhibitor
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
